Poseida Therapeutics’ (PSTX) “Neutral” Rating Reiterated at BTIG Research

BTIG Research reissued their neutral rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a report released on Tuesday,Benzinga reports.

PSTX has been the subject of a number of other reports. HC Wainwright reaffirmed a “neutral” rating and set a $9.00 target price (down from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday.

Poseida Therapeutics Stock Performance

Shares of NASDAQ:PSTX opened at $9.38 on Tuesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The firm has a market cap of $914.17 million, a PE ratio of -14.89 and a beta of 0.54. The firm’s 50 day simple moving average is $2.90 and its 200-day simple moving average is $2.97. Poseida Therapeutics has a one year low of $1.87 and a one year high of $9.41.

Institutional Trading of Poseida Therapeutics

Hedge funds have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company raised its position in shares of Poseida Therapeutics by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock worth $83,000 after acquiring an additional 3,552 shares in the last quarter. Rhumbline Advisers raised its holdings in Poseida Therapeutics by 4.2% in the second quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock worth $283,000 after purchasing an additional 3,875 shares in the last quarter. American Century Companies Inc. raised its holdings in Poseida Therapeutics by 5.9% in the second quarter. American Century Companies Inc. now owns 90,487 shares of the company’s stock worth $264,000 after purchasing an additional 5,023 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Poseida Therapeutics by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock valued at $1,749,000 after buying an additional 9,672 shares during the last quarter. Finally, Bayesian Capital Management LP purchased a new position in shares of Poseida Therapeutics in the 1st quarter worth approximately $33,000. Hedge funds and other institutional investors own 46.87% of the company’s stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.